Abstract 457P
Background
Vitamin D deficiency is associated with various kinds of cancer. Moreover, vitamin D level possibly has an inverse relationship with cancer mortality. The data on vitamin D status among Thai cancer patients and its association with cancer survival are scarce. Objectives: The primary outcome was to determine the prevalence of vitamin D deficiency among unselected Thai cancer patients. The secondary outcomes were to explore the effect of cancer treatment upon vitamin D status, the independent predictive factor(s) of vitamin D deficiency among cancer patients and its potential independent factor of cancer survival.
Methods
There were 106 consecutive cancer patients participated in this prospective descriptive study conducted at Division of Medical Oncology. Vitamin D (25(OH) D) levels were collected before and after cancer treatment. Demographic data, vitamin D status, and treatment outcomes were collected and analysed.
Results
There were 106 consecutive cancer patients participated in this study. Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators found that almost all of the cancer patients had vitamin D deficiency (102 of 106, 96.2%). Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators did not demonstrate the significant change of vitamin D level (mean change = -1.46 (95% C.I., -3.33-0.41), p = 0.124) when the blood samples were collected before and after cancer treatment. Therefore, cancer treatment was unlikely to affect the vitamin D status. There was a trend towards inverse relationship between the BMI and vitamin D level. At the median follow-up time of 254.5 days (IQR 220-297), the investigators revealed that low BSA (BSA < 1.5 m2), PS 2 at presentation was the independent predictive factors of survival, according to the multi-variate analysis.
Conclusions
Nearly all Thai cancer patients have vitamin D deficiency. Cancer treatment does not affect the vitamin D status. Low serum vitamin D level does not affect survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chavapon Ngokngarm/Vajira hospital, Thailand.
Funding
Medical Research Fund of Faculty Medicine Vajira Hospital, Navamindradhiraj University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract